Aytu Biopharma (AYTU) Net Cash Flow (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Net Cash Flow data on file, last reported at -$3.3 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 48.76% year-over-year to -$3.3 million in Q1 2026; TTM through Mar 2026 was $8.5 million, a 638.25% increase from a year earlier, with the FY2025 full-year figure at $10.9 million, up 467.44% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$3.3 million, down from -$2.6 million in the prior quarter.
• Over the last five years, Net Cash Flow for AYTU reached as high as $12.8 million in Q2 2025 and fell as low as -$8.3 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$503647.1 across 5 years, with a median of -$328000.0 in 2023.
• On a YoY basis, Net Cash Flow climbed as much as 5094.72% in 2025 and fell as far as 1063.2% in 2025.
• Year by year, Net Cash Flow stood at -$4.4 million in 2022, then soared by 90.02% to -$435000.0 in 2023, then jumped by 166.67% to $290000.0 in 2024, then tumbled by 998.28% to -$2.6 million in 2025, then decreased by 27.06% to -$3.3 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$3.3 million in Q1 2026, -$2.6 million in Q4 2025, and $1.7 million in Q3 2025.